KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Fulgent Genetics (FLGT) Debt to Equity (2020 - 2026)

Fulgent Genetics' Debt to Equity history spans 7 years, with the latest figure at $0.03 for Q1 2026.

  • On a quarterly basis, Debt to Equity rose 16.38% to $0.03 in Q1 2026 year-over-year; TTM through Mar 2026 was $0.03, a 16.38% increase, with the full-year FY2025 number at $0.03, up 1.54% from a year prior.
  • Debt to Equity hit $0.03 in Q1 2026 for Fulgent Genetics, up from $0.03 in the prior quarter.
  • Over the last five years, Debt to Equity for FLGT hit a ceiling of $0.03 in Q1 2026 and a floor of $0.01 in Q4 2022.
  • Historically, Debt to Equity has averaged $0.02 across 5 years, with a median of $0.03 in 2024.
  • Biggest five-year swings in Debt to Equity: surged 214.26% in 2022 and later crashed 48.19% in 2023.
  • Tracing FLGT's Debt to Equity over 5 years: stood at $0.01 in 2022, then soared by 101.56% to $0.02 in 2023, then grew by 17.73% to $0.03 in 2024, then increased by 1.54% to $0.03 in 2025, then increased by 13.54% to $0.03 in 2026.
  • Business Quant data shows Debt to Equity for FLGT at $0.03 in Q1 2026, $0.03 in Q4 2025, and $0.03 in Q3 2025.